Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts.

Autor:	Kuo WI; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Cheng KH; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Chang YJ; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Wu TT; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Hsu WC; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Chen LC; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C., Chang CH; Isotope Application Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C. chchang@iner.gov.tw.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2019 Jan; Vol. 39 (1), pp. 183-190.
DOI:	10.21873/anticanres.13096
Abstrakt:	Background/aim: Cetuximab has exhibited high EGFR-targeting specificity and clinical promise in previous studies. In this study, we formulated unit dose kits for preparation of high specific activity 188 Re-cetuximab for imaging and treatment of EGFR-positive cancer. Materials and Methods: 188 Re-cetuximab was prepared by adding 0.37-0.74 GBq/0.5 ml of 188 Re-perrhenate for 4 h at 37°C. Cell surface expression of EGFR, cell binding and cytotoxic effects were evaluated in vitro using both EGFR-positive (NCI-H292, A431) and EGFR-negative (BT483) tumors. A nanoSPECT/CT imaging study was performed in mice bearing EGFR-expressing NCI-H292 tumors. Results: 188 Re-cetuximab bound specifically to EGFR-expressing cells and labeling of radionuclides to cetuximab preserved the binding ability of the antibody. Besides, the cytotoxic effect of 188 Re-cetuximab was increased dose-dependently. NanoSPECT/CT imaging revealed that 188 Re-cetuximab could continually target the tumor region for at least 48 h. Conclusion: The highly specific targeted property of 188 Re-cetuximab suggested that it is suitable as a diagnostic tool and maybe a potent radioimmunotherapy agent in EGFR-positive cancers. (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu